News
We send the latest information from SMC Laboratories.
National Defense Medical College's publication in Surgery Open Science
SMC announces that National Defense Medical College (Japan) has published the results of a study using STAM™ mouse model in Surery Open Science. Title: “In vivo diffuse reflectance spectroscopic analysis of fatty liver with inflammation in mice” In this paper, they report the usefulness of diffuse reflectance spectroscopy, which does not require tissue collection,…
The virtual 81st Scientific Sessions of the American Diabetes Association® and updated information on our original NASH-HCC model (STAM™)
We recently made a presentation on our STAM™ mouse at the 81st Annual Meeting of the American Diabetes Association (June 25 to 29, 2021). The abstract of the presentation has been published in Diabetes. 209-LB: RNA-Seq Analysis of Liver from Diabetic and NASH Model Mouse Treated with Streptozotocin, High-Fat Diet | Diabetes (diabetesjournals.org)
Introducing our new model: Liver Orthotopic Xenograft mouse model
We’re getting in touch today with an announcement regarding the addition of the Liver Orthotopic Xenograft mouse model to our model line-up – a cancer model that also allows the evaluation of the tumor microenvironment. The number of deaths from cancer continues to rise as medical advances extend life spans. Therefore, there is a…
Our clients’ presentations at DDW 2021
Our clients presented data on treatment of NASH using STAMTM model at the DDW2021 (May 21-23). For detailed information, see the below URL. https://ddw.org/attendee-planning/online-planner/ Poster #Sa373 BOFUTSUSHOSAN, A TRADITIONAL JAPANESE MEDICINE, MAINTAINS THE GUT MICROBIOME AND AMELIORATES PROGRESSION OF LIVER DISORDER IN DIABETES INDUCED NASH MODEL MICE Institution: Hokkaido University (Japan)
SMC announces Presentation of New Data at the 81st Annual Meeting of the American Diabetes Association
We are pleased to announce the acceptance of our abstract, “RNA-seq Analysis of Liver from Diabetic and NASH Model Mouse Treated with Streptozotocin, High-Fat Diet”, for presentation in the category “Integrated Physiology—Liver” at the 81st Annual Meeting of the American Diabetes Association, to be held from June 25 to 29, 2021. The poster will…
Visit SMC Laboratories at BIO Digital 2021
We are joining the world’s largest virtual biotech partnering and education event, convening thousands of global biotech leaders and innovators. The virtual gathering of the global biotech industry provides access to key partners via BIO One-on-One Partnering, educational resources, and the valuable insights for research and development. Main Conference Webpage SMC Laboratories Inc's…
New Partnership with cancer model search service Repositive, Inc.
SMC Laboratories, Inc. is pleased to announce a partnership with Repositive, Inc., a UK-based bespoke cancer model search service. Repositive supports researchers working in oncology to find the right cancer models for their studies. They also organise and curate cancer model data from partner CROs, and present this inventory of models online, via their beta…
Amplia Therapeutics has publshed a pres releaes regarding the AMP945 and AMP886 efficacy evaluation study for NASH we have provied.
Amplia Therapeutics, which is our client, has announced the results of pharmacology study using a STAM™ mouse model. For detail information, see the Amplia's press release. https://www.ampliatx.com/site/PDF/fd3f2d1f-9d2b-4fff-a6ad-13a3ea8d4956/ATXFAKInhibitorsReduceFibrosisinAnimalModelofNASH
Chemomab announces enrollment of first patient in phase 2a study of CM-101 in NASH
Chemomab Ltd.(Israel) announced on 26 April, 2021, enrollment of first patient in phase 2a study of CM-101 in NASH. For detailed information, see the below URL. https://www.prnewswire.com/news-releases/chemomab-announces-enrollment-of-first-patient-in-phase-2a-study-of-cm-101-in-non-alcoholic-steatohepatitis-nash-301276524.html?tc=eml_cleartime CM-101, a monoclonal antibody designed to bind and block CCL24 activity. The antibody used the STAM™ mouse model for non-clinical studies, and data showing the improvement…
Pre-clinical studies for cirrhosis: Carbon tetrachloride (CCl4)-induced liver fibrosis
The CCl4-induced liver fibrosis model is a model that forms bridging fibrosis around the portal vein region. While our STAM™ model develops mild liver fibrosis, the CCl4 model develops severe cirrhosis-like fibrosis. We also offer pharmacological studies with the positive control ”Valsartan”. As its study period is relatively short, only 4 weeks, the model…